We are live on ! Find out more
CTA

Chesley Taft & Associates Portfolio holdings

AUM $2.57B
1-Year Est. Return 22.93%
This Fund
S&P 500
This Quarter Est. Return
+6.96%
1 Year Est. Return
+22.93%
3 Year Est. Return
+80.85%
5 Year Est. Return
+97.37%
10 Year Est. Return
+353.09%
AUM
$1.74B
AUM Growth
+$64.3M
Cap. Flow
-$11.6M
Cap. Flow %
-0.67%
Top 10 Hldgs %
28.25%
Holding
295
New
7
Increased
110
Reduced
109
Closed
1

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$11.2M
2
SHW icon
Sherwin-Williams
SHW
+$8.84M
3
DHR icon
Danaher
DHR
+$5.1M
4
V icon
Visa
V
+$4.2M
5
BALL icon
Ball Corp
BALL
+$1.48M

Sector Composition

Rank Sector Weight
1 Technology 20.03%
2 Healthcare 14.57%
3 Financials 11.1%
4 Communication Services 9.17%
5 Consumer Discretionary 7.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RTX icon
76
RTX Corp
RTX
$292B
$5.39M 0.31%
63,232
+207
+0.3% +$17.4K
WFC icon
77
Wells Fargo
WFC
$266B
$5.34M 0.31%
117,910
+5,465
+5% +$244K
VO icon
78
Vanguard Morningstar Mid-Cap ETF
VO
$108B
$5.32M 0.31%
89,672
+10,640
+13% +$617K
LLY icon
79
Eli Lilly
LLY
$1,000B
$5.11M 0.29%
22,255
+110
+0.5% +$22.1K
IBB icon
80
iShares Biotechnology ETF
IBB
$9.18B
$5.07M 0.29%
30,956
+85
+0.3% +$13.1K
VTI icon
81
Vanguard Morningstar Total Stock Market ETF
VTI
$670B
$5.03M 0.29%
22,586
+387
+2% +$84K
BLK icon
82
Blackrock
BLK
$175B
$4.95M 0.28%
5,654
-123
-2% -$104K
LOW icon
83
Lowe's Companies
LOW
$119B
$4.72M 0.27%
24,357
-470
-2% -$92K
EW icon
84
Edwards Lifesciences
EW
$51.1B
$4.66M 0.27%
44,959
-610
-1% -$57.5K
LIN icon
85
Linde
LIN
$222B
$4.49M 0.26%
15,532
-425
-3% -$124K
MRK icon
86
Merck
MRK
$316B
$4.45M 0.26%
57,260
-3,068
-5% -$228K
CVX icon
87
Chevron
CVX
$385B
$4.42M 0.25%
42,154
-981
-2% -$104K
SHW icon
88
Sherwin-Williams
SHW
$86B
$4.39M 0.25%
16,103
-32,266
-67% -$8.84M
SHM icon
89
State Street SPDR Nuveen ICE Short Term Municipal Bond ETF
SHM
$3.46B
$4.29M 0.25%
86,669
+950
+1% +$47.1K
CCI icon
90
Crown Castle
CCI
$33.5B
$4.21M 0.24%
21,600
+535
+3% +$100K
IGIB icon
91
iShares 5-10 Year Investment Grade Corporate Bond ETF
IGIB
$18.5B
$4.13M 0.24%
68,313
+5,000
+8% +$299K
ZTS icon
92
Zoetis
ZTS
$32.3B
$4M 0.23%
21,448
-954
-4% -$166K
TGT icon
93
Target
TGT
$67.8B
$3.93M 0.23%
16,254
FITB
94
Fifth Third Bancorp
FITB
$51.6B
$3.88M 0.22%
101,415
+665
+0.7% +$26.6K
CZR icon
95
Caesars Entertainment
CZR
$6.06B
$3.66M 0.21%
35,302
-2,500
-7% -$252K
VTV icon
96
Vanguard Morningstar Value ETF
VTV
$189B
$3.59M 0.21%
26,132
+3,425
+15% +$471K
ADP icon
97
Automatic Data Processing
ADP
$107B
$3.58M 0.21%
18,009
-240
-1% -$46.6K
TXN icon
98
Texas Instruments
TXN
$246B
$3.53M 0.2%
18,375
+25
+0.1% +$4.69K
NVS icon
99
Novartis
NVS
$292B
$3.53M 0.2%
38,672
+460
+1% +$41K
VTIP icon
100
Vanguard Short-Term Inflation-Protected Securities Index Fund
VTIP
$19.1B
$3.51M 0.2%
67,056
+11,105
+20% +$579K

Similar funds

Chesley Taft & Associates's Q2 2021 Portfolio in Review

As of Q2 2021, Chesley Taft & Associates held 295 positions worth $1.74B, up 3.8% from $1.67B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Trading was light in Q2 2021: portfolio turnover was 2.7%. Chesley Taft & Associates opened 7 new positions and exited 1, leaving the 295-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.

  • Chesley Taft & Associates's largest Q2 2021 buy was Humana: 24,190 shares worth $10.7M.
  • Chesley Taft & Associates added most to Broadcom in Q2 2021, an estimated $6.12M increase.
  • Chesley Taft & Associates's biggest Q2 2021 reduction was Amgen, cutting an estimated $11.2M.
  • Chesley Taft & Associates fully exited Ball Corp in Q2 2021, selling an estimated $1.48M.
  • Chesley Taft & Associates's ten largest holdings make up 28% of its $1.74B portfolio in Q2 2021.
  • Chesley Taft & Associates opened 7 new positions and closed 1 in Q2 2021.
  • Chesley Taft & Associates's portfolio value rose 3.8% quarter-over-quarter to $1.74B.

Based on Chesley Taft & Associates's 13F filing for Q2 2021, filed 7 Jul 2021.